Sign In
Linkedin Youtube
EN ES

Publications

Publication Type
Keywords
Publication Year

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer

Article
Author:
Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MA, Hoff PM, Espié M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F.
Parent Trial:

SOLTI-0701 SORAFENIB FASEII

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

Article
Author:
Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E, Gaion F, Bari M, Morandi P, Valagussa P, Gianni L.
Parent Trial:

ECTO II (FM-B04-01)

Título de la publicación: (SÍ/NO e incluir en la carpeta) Design of RESILIENCE: a phase (PH) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (TX) of locally advanced (ADV) or metastatic HER2-negative breast cancer (BC).

Congress Communications
Author:
Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ.
Parent Trial:

RESILIENCE (BAY 43-9006)

Phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE).

Congress Communications
Author:
Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ.
Parent Trial:

RESILIENCE (BAY 43-9006)

Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P)

Congress Communications
Author:
J. A. Lopez-Martin, M. Vidal Losada, J. Cortes, B. Bermejo, A. Lluch Fernandez, M. Learoyd, A. Saunders, M. Stuart, J. Baselga
Parent Trial:

AZD8931 - THYME

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer

Article
Author:
Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston S J, Grieve R J, Barrett-Lee P J, Thorpe H.
Parent Trial:

AZURE

Breast-cancer adjuvant therapy with zoledronic acid

Article
Author:
Coleman R, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Davies C, Hiley V, Gregory W and Bell R on behalf of the AZURE investigators.
Parent Trial:

AZURE

Discordant treatment effects according to menopausal status following adjuvant zoledronic acid in stage ll/lll breast cancer –the AZURE trial (BIG 01/04)

Congress Communications
Author:
Coleman R, Marshall H, Gregory W, Bell R, Dodwell D, Keane M, Gil M, Davies C, Cameron D.
Parent Trial:

AZURE

Pegylated liposomal doxorubicin (PLD) as primary treatment in estrogen receptor (ER) and Her2 poor breast cancer and risk of developing cardiotoxicity or elderly patients (PT). Results from the phase II CAPRICE study

Congress Communications
Author:
Gil MJ, Bellet MC, Llombart A, Ojeda B, Manso L, Mesia C, Morales S, García-Martinez H, Martínez N, Melé M, Fernández-Ortega A, Baselga
Parent Trial:

CAPRICE

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Article
Author:
Gianni L, Dafni U, Gelber R, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart M, Shen Z, Skiadopoulos G, Procter M, Pritchard K, Piccart-Gebhart M, and Bell R, for the Herceptin Adjuvant (HERA) Trial Study Team.
Parent Trial:

HERA
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  
X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.